


ASSAY DESCRIPTION

In Matrico® Human IPF Protein Secretion Assay is a clinically-relevant cell-based 3D assay integrating primary human lung fibroblasts and IPF decellularized ECM (dECM) from patients.


- contains IPF biochemical and mechanical signals
- validated with Pirfenidone and Nintedanib
- results consistent with IPF patient data

ECM type	Human IPF dECM
Cell type	Human lung fibroblasts
Plate format	24-well
Endpoint	72 hours
Markers analyzed	ProCol1, ProCol3, CTGF
Analytical method	ELISA (Supernatant)


ASSAY SETUP



ASSAY WORKFLOW



ASSAY VALIDATION



Assay validation with antifibrotic drugs. (A) Simtuzumab (50µg/mL), a monoclonal antibody against lysyl oxidase-like 2 (LOXL2). **(B)** Nintedanib (1µM). **(C)** Pamrevlumab (100µg/mL), a monoclonal antibody against connective tissue growth factor (CTGF). * p<0.05, ** p<0.01.